Literature DB >> 31371179

Pharmacist roles, training, and perceived barriers in naloxone dispensing: A systematic review.

Tanvee Thakur, Meredith Frey, Betty Chewning.   

Abstract

OBJECTIVES: Pharmacists are well positioned to identify patients at risk of overdose, dispense naloxone, and counsel patients on appropriate use. In response to growing numbers of opioid-related deaths, many states have issued standing orders allowing pharmacists to dispense naloxone without a prescription. This systematic review examines the current state of naloxone use and dispensing regarding (1) roles for pharmacists dispensing naloxone, (2) barriers to their dispensing naloxone, and (3) pharmacist training to dispense naloxone. DATA SOURCES: PubMed, Cinahl Plus, and Cochrane review databases were searched with the use of the terms "pharmacist OR pharmacy" AND "naloxone." Included for review were peer-reviewed original research studies conducted in the U.S. in the past 5 years. STUDY SELECTION: The preliminary search generated 155 studies, including 50 duplicate studies which were removed. From the remaining 105 studies, 33 were included that addressed pharmacist naloxone dispensing roles, barriers and facilitators to dispensing, or training for pharmacists. DATA EXTRACTION: Authors, publication year, study title, study objective, method, outcomes, and conclusions were extracted for all studies.
RESULTS: Out of 33 studies, 14 focused on pharmacists' roles in naloxone dispensing, 9 on barriers, and 10 on training pharmacists for dispensing naloxone. The review found that most states permit major naloxone dispensing roles for pharmacists, but pharmacists are often underutilized without programs to support their roles. A key barrier to pharmacist naloxone dispensing is limited pharmacist training to identify and educate patients at risk of overdose.
CONCLUSION: Although pharmacists have the legal opportunity to educate patients and dispense naloxone, barriers have limited their addressing naloxone with patients. There is a need for more intervention studies and in-depth understanding of pharmacist perspectives on barriers, training, and professional roles to facilitate tailored approaches for increasing pharmacist confidence in naloxone dispensing and consultation.
Copyright © 2020 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31371179     DOI: 10.1016/j.japh.2019.06.016

Source DB:  PubMed          Journal:  J Am Pharm Assoc (2003)        ISSN: 1086-5802


  14 in total

1.  Prescribers and Naloxone Pharmacy Claims.

Authors:  Rosanna Smart; Caroline K Geiger; Christopher M Jones; Bradley D Stein
Journal:  J Gen Intern Med       Date:  2020-08       Impact factor: 5.128

2.  Modifying and Evaluating the Opioid Overdose Knowledge Scale for Prescription Opioids: A Pilot Study of the Rx-OOKS.

Authors:  Jo Ann Shoup; Shane R Mueller; Ingrid A Binswanger; Anna V Williams; John Strang; Jason M Glanz
Journal:  Pain Med       Date:  2020-10-01       Impact factor: 3.750

3.  Evaluation of naloxone furnishing community pharmacies in San Francisco.

Authors:  Andy M Nguyen; Thomas E Kearney; Dorie E Apollonio
Journal:  J Am Pharm Assoc (2003)       Date:  2020-09-15

4.  Buprenorphine and naloxone access in pharmacies within high overdose areas of Los Angeles during the COVID-19 pandemic.

Authors:  David Dadiomov; Maria Bolshakova; Melania Mikhaeilyan; Rebecca Trotzky-Sirr
Journal:  Harm Reduct J       Date:  2022-06-29

5.  Communication between patients and health care professionals about opioid medications.

Authors:  Tanvee Thakur; Meredith Frey; Betty Chewning
Journal:  Explor Res Clin Soc Pharm       Date:  2021-05-29

6.  Assessing pharmacy-based naloxone access using an innovative purchase trial methodology.

Authors:  Robin A Pollini; Rebecca Joyce; Jenny E Ozga-Hess; Ziming Xuan; Traci C Green; Alexander Y Walley
Journal:  J Am Pharm Assoc (2003)       Date:  2020-07-08

7.  Individual and Community Factors Associated with Naloxone Co-prescribing Among Long-term Opioid Patients: a Retrospective Analysis.

Authors:  Bradley D Stein; Rosanna Smart; Christopher M Jones; Flora Sheng; David Powell; Mark Sorbero
Journal:  J Gen Intern Med       Date:  2021-02-17       Impact factor: 6.473

8.  Pharmacists' roles in supporting people living with severe and persistent mental illness: a systematic review protocol.

Authors:  Sarira El-Den; Sara S McMillan; Amanda J Wheeler; Ricki Ng; Helena Roennfeldt; Claire L O'Reilly
Journal:  BMJ Open       Date:  2020-07-13       Impact factor: 2.692

9.  A survey of Alberta pharmacists' attitudes, comfort and perceived barriers to a community-based naloxone program.

Authors:  Sarah-Emily Nowlan; Neil J MacKinnon; Ana Hincapie; Matt Tachuk
Journal:  Can Pharm J (Ott)       Date:  2021-06-18

10.  Effectiveness and implementability of state-level naloxone access policies: Expert consensus from an online modified-Delphi process.

Authors:  Rosanna Smart; Sean Grant
Journal:  Int J Drug Policy       Date:  2021-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.